Profile data is unavailable for this security.
About the company
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
- Revenue in GBP (TTM)20.88m
- Net income in GBP-36.17m
- Incorporated2015
- Employees73.00
- LocationShield Therapeutics PLC3rd FlBaltic Business Quarters, Abbott's HillGATESHEAD NE8 3DUnited KingdomGBR
- Phone+44 19 1511 8500
- Websitehttps://www.shieldtherapeutics.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Genflow Biosciences PLC | 0.00 | -1.63m |
Synairgen plc | 0.00 | -6.92m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
LungLife AI Inc | 21.69k | -3.34m |
Oxford Biodynamics PLC | 617.00k | -11.11m |
OptiBiotix Health PLC | 644.00k | -2.04m |
Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m |
Skinbiotherapeutics PLC | 161.65k | -2.88m |
Arecor Therapeutics PLC | 4.57m | -8.55m |
Sareum Holdings Plc | 0.00 | -4.26m |
Incanthera PLC | 0.00 | -1.55m |
Shield Therapeutics PLC | 20.88m | -36.17m |
Poolbeg Pharma PLC | 0.00 | -4.38m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 23 Apr 2024 | 64.05m | 8.19% |
Jupiter Asset Management Ltd.as of 21 Jul 2023 | 34.13m | 4.36% |
Premier Fund Managers Ltd.as of 05 May 2023 | 30.00m | 3.84% |
LGT Capital Partners AG (Investment Management)as of 01 Aug 2024 | 28.70m | 3.67% |
IG Markets Ltd.as of 01 Aug 2024 | 12.82m | 1.64% |
Killik & Co. LLPas of 05 May 2023 | 10.62m | 1.36% |
Jarvis Investment Management Ltd.as of 01 Aug 2024 | 9.61m | 1.23% |
KW Investment Management Ltd.as of 01 Aug 2024 | 9.35m | 1.20% |
Rahn+Bodmer Co.as of 01 Aug 2024 | 5.72m | 0.73% |
USS Investment Management Ltd.as of 19 Mar 2021 | 5.07m | 0.65% |